Patents Assigned to Genentech
  • USP30 INHIBITORS AND METHODS OF USE
    Publication number: 20200172911
    Abstract: Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 4, 2020
    Applicant: Genentech, Inc.
    Inventors: Yingnan Zhang, Baris Bingol, Jacob Corn
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20200171029
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Application
    Filed: September 11, 2019
    Publication date: June 4, 2020
    Applicant: Genentech, Inc.
    Inventors: Anthony ESTRADA, Alan G. OLIVERO, Snahel PATEL, Michael SIU, Joseph LYSSIKATOS
  • METHODS OF TREATING LUNG CANCER WITH A PD-1 AXIS BINDING ANTAGONIST, AN ANTIMETABOLITE, AND A PLATINUM AGENT
    Publication number: 20200171146
    Abstract: The present disclosure provides methods for treating lung cancer (such as non-small cell lung cancer, e.g., Stage IV non-squamous non-small cell lung cancer) in an individual. The methods comprise administering to the individual a PD-1 axis binding antagonist (such as an anti-PD-L1 antibody, e.g., atezolizumab), an antimetabolite (e.g., pemetrexed), and a platinum agent (e.g., cisplatin or carboplatin).
    Type: Application
    Filed: July 18, 2019
    Publication date: June 4, 2020
    Applicant: Genentech, Inc.
    Inventors: Geetha SHANKAR, Alan SANDLER, Daniel ShinYu CHEN, WeiYu LIN
  • ERBB2/HER2 MUTATIONS IN THE TRANSMEMBRANE OR JUXTAMEMBRANE DOMAIN
    Publication number: 20200172631
    Abstract: The present disclosure relates to somatic ErbB2 mutations in cancer and provides methods of identifying, diagnosing, and prognosing ErbB2-positive cancers. The present disclosure further provides methods of treating cancer, including certain subpopulations of patients. The mutations are in the transmembrane domain or juxtamembrane domain of ErbB2.
    Type: Application
    Filed: October 24, 2019
    Publication date: June 4, 2020
    Applicant: GENENTECH, INC.
    Inventor: Somasekar Seshagiri
  • Methods for diagnosing and treating inflammatory bowel disease
    Patent number: 10669587
    Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: June 2, 2020
    Assignee: GENENTECH, INC.
    Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
  • INHALED POWDER FORMULATIONS
    Publication number: 20200165260
    Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Applicant: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Paul Gibbons, Terry Kellar, Wei Li, Rohan Mendonca, Po-wai Yuen, Mark Edward Zak, Lei Zhang
  • METHODS OF DIAGNOSING AND TREATING EOSINOPHILIC DISORDERS
    Publication number: 20200165679
    Abstract: Methods of diagnosing and treating disorders related to excess eosinophil numbers or activity, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.
    Type: Application
    Filed: November 1, 2019
    Publication date: May 28, 2020
    Applicant: Genentech, Inc.
    Inventors: ALEXANDER R. ABBAS, JOSEPH R. ARRON, DAVID F. CHOY, GUIQUAN JIA, NICHOLAS J.I. LEWIN-KOH, KATRINA B. MORSHEAD
  • Method to improve virus filtration capacity
    Patent number: 10662237
    Abstract: The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: May 26, 2020
    Assignee: Genentech, Inc.
    Inventor: Amit Mehta
  • Hinge modified antibody fragments and methods of making
    Patent number: 10662254
    Abstract: The instant disclosure provides antibody fragments (e.g., Fab and F(ab?)2) having reduced or no reactivity towards pre-existing anti-hinge antibodies (AHA) and compositions comprising such antibody fragments, as well as methods of making and using such antibody fragments and compositions.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 26, 2020
    Assignee: Genentech, Inc.
    Inventors: Yu-Ju G. Meng, Hok Seon Kim, Ingrid Kim, Christoph Spiess
  • HERCEPTIN® ADJUVANT THERAPY
    Publication number: 20200155701
    Abstract: The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 21, 2020
    Applicant: GENENTECH, INC.
    Inventor: John L. Bryant
  • PERTUZUMAB VARIANTS AND EVALUATION THEREOF
    Publication number: 20200157238
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Application
    Filed: August 6, 2019
    Publication date: May 21, 2020
    Applicant: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS
    Publication number: 20200157235
    Abstract: The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
    Type: Application
    Filed: July 10, 2019
    Publication date: May 21, 2020
    Applicant: Genentech, Inc.
    Inventors: Craig Smith, Peter S. Chin
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS
    Publication number: 20200155676
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.
    Type: Application
    Filed: June 26, 2019
    Publication date: May 21, 2020
    Applicant: Genentech, Inc.
    Inventors: Jane GROGAN, Yuanyuan XIAO, Patrick CAPLAZI, Steve LIANOGLOU, Jason HACKNEY, Eugene Yu-Chuan CHIANG
  • METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS
    Publication number: 20200155520
    Abstract: Provided herein are therapies including dosage regimens for the treatment of cancer using B-RAF and an immune checkpoint inhibitor in combination with and/or without a MEK inhibitor.
    Type: Application
    Filed: November 13, 2019
    Publication date: May 21, 2020
    Applicant: Genentech, Inc.
    Inventors: Dawn Colburn, Nicole Richie
  • Heteroaryl estrogen receptor modulators and uses thereof
    Patent number: 10654867
    Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: May 19, 2020
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Jiangpeng Liao
  • Anti-Ly6E antibodies and immunoconjugates and methods of use
    Patent number: 10653792
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of treating cancer using the same.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: May 19, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Chang, Chie Sakanaka
  • 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
    Patent number: 10654824
    Abstract: The invention relates to compounds of formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, R4a, R4b and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: May 19, 2020
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Aleksandr Kolesnikov, Jianwen A. Feng
  • Anti-factor D antibody variant conjugates and uses thereof
    Patent number: 10654932
    Abstract: The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 19, 2020
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Robert F. Kelley, Justin M. Scheer, Whitney Shatz, Devin Tesar, Menno van Lookeren Campagne
  • Formulations with reduced oxidation
    Patent number: 10653779
    Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 19, 2020
    Assignee: GENENTECH, INC.
    Inventors: Sreedhara Alavattam, Mary Mallaney, Parbir Grewal
  • Method for treating joint damage
    Patent number: 10654940
    Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 19, 2020
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG, Biogen Inc.
    Inventors: Mark Totoritis, Timothy Mark Shaw, Sunil Agarwal, David Yocum, Ariella Kelman